Compare Novartis AG (NVS) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Yum China Holdings Inc — how do they compare? Novartis AG trades at $143.75 (market cap $268.57B), while Yum China Holdings Inc trades at $42.92 (market cap $14.11B). The key difference: Novartis AG is far larger — about 19× Yum China Holdings Inc's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Yum China Holdings Inc for 77 Days on average.
| NVS | YUMC | |
|---|---|---|
Market Cap | $268.57B | $14.11B |
Volume | 1,532,573 | 2,350,650 |
Sector | Health | Consumer Cyclical |
52-Week High | $168.62 | $57.95 |
52-Week Low | $121.80 | $39.98 |
Typical Hold Time | 82 Days | 77 Days |
Enterprise Value | $309.89B | $15.02B |
Dividend Yield | 3.31% | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVS trades at $143.11, down 0.12% on the day, with a bearish technical signal and mixed earnings history including a recent Q1 2026 miss. The company maintains strong profitability with a 22.5% net income margin and 30.55% ROE, while recent news highlights a major $7.8B licensing deal with China's Abogen and ongoing investor scrutiny following clinical trial setbacks.
The outlook is cautious; analyst consensus is a Hold with a $146 price target, but risks include pipeline disappointments and M&A execution. Upside hinges on successful drug launches and deal integration, while downside stems from competitive pressures and regulatory challenges.
YUMC trades at $41.78, up 2.78% today, but technical indicators signal a bearish trend with strong sell signals from moving averages. Fundamentally, the company shows steady revenue growth, reaching $11.80B in 2025, with consistent earnings beats in recent quarters. Recent developments include the acquisition of Pizza Hut brand ownership in mainland China and expansion of Pizza Hut Burger Bars to 300 locations.
The outlook is mixed: strong analyst consensus (73.68% buy ratings) and a projected 25.63% upside suggest value, but bearish technicals and competitive pressures pose risks. Investors should weigh solid fundamentals against near-term price volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
